Healio
Biykem Bozkurt told the Cardiometabolic Health Congress that semaglutide and tirzepatide improve weight, exercise capacity and quality of life in obese HFpEF patients.
Recap by typeshit. Full story at Healio.
Early uptake of the Wegovy pill outpaced injectable incretin weight loss drugs at a similar stage, HealthDay reported on Oct. 22.
Leftover food can't tell researchers whether someone stopped eating from fullness or from feeling sick, and Medical Xpress explains why that gap matters.
Moss says he once believed GLP-1s caused far more muscle loss than ordinary calorie cutting. He now says he got that wrong.
Topol points to neoantigens, the proteins or peptides on cancer cell surfaces, as the base of personalized cancer therapies.
The roundup also covers telehealth firms marketing off-label GLP-1s for addiction and a Treasury rule adding scrutiny to licensing deals with Chinese biotechs.
Reuters reports on GLP-1 users turning to repair shops as their bodies change. Tap through for the full story on where the drugs are reaching everyday businesses.
Loading…